Cyto-Sen Therapeutics

Orlando, United States Founded: 2014 • Age: 12 yrs Acquired By Kiadis Pharma
NK cell therapies are developed for acute myeloid leukemia treatment.

About Cyto-Sen Therapeutics

Cyto-Sen Therapeutics is a company based in Orlando (United States) founded in 2014 was acquired by Kiadis Pharma in April 2019.. Cyto-Sen Therapeutics has raised $800 thousand across 1 funding round from investors including Kiadis Pharma. Cyto-Sen Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.

  • Headquarter Orlando, United States
  • Sectors
    Healthcare
    Technology
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Technology → Quantum & Emerging Technologies
Healthcare → Healthcare Products & Supplies
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $800 K (USD)

    in 1 rounds

  • Latest Funding Round
    $800 K (USD), Seed

    Dec 13, 2016

  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    Kiadis Pharma

    (Apr 17, 2019)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Cyto-Sen Therapeutics

Cyto-Sen Therapeutics has successfully raised a total of $800K through 1 strategic funding round. The most recent funding activity was a Seed round of $800 thousand completed in December 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Seed — $800,000
  • First Round

    (13 Dec 2016)

  • Investors Count
Date Amount Transaction Name Valuation Lead Investors Investors
Dec, 2016 Amount Seed - Cyto-Sen Therapeutics Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Cyto-Sen Therapeutics

Cyto-Sen Therapeutics has secured backing from 1 investor. Prominent investors backing the company include Kiadis Pharma. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Investor Description Founded Year Domain Location
Therapeutic solutions for hematopoietic stem cell transplants are developed.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Cyto-Sen Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Cyto-Sen Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Cyto-Sen Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Cyto-Sen Therapeutics

Cyto-Sen Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
domain founded_year HQ Location
Small molecule therapeutics for cancer treatment are developed.
domain founded_year HQ Location
Cancer therapies are developed using selective pathway inhibitors.
domain founded_year HQ Location
MicroRNA-based therapeutics are developed for treating multiple diseases.
domain founded_year HQ Location
Therapeutics for cancer and rare diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Cyto-Sen Therapeutics

When was Cyto-Sen Therapeutics founded?

Cyto-Sen Therapeutics was founded in 2014 and raised its 1st funding round 2 years after it was founded.

Where is Cyto-Sen Therapeutics located?

Cyto-Sen Therapeutics is headquartered in Orlando, United States. It is registered at Orlando, Florida, United States.

Is Cyto-Sen Therapeutics a funded company?

Cyto-Sen Therapeutics is a funded company, having raised a total of $800K across 1 funding round to date. The company's 1st funding round was a Seed of $800K, raised on Dec 13, 2016.

What does Cyto-Sen Therapeutics do?

Cyto-Sen Therapeutics was founded in 2014 in Orlando, United States, within the biotechnology sector focused on oncology. Proprietary nanoparticle-based methods are employed to expand and activate natural killer (NK) cells for cancer therapies. The lead product targets acute myeloid leukemia and is currently in Phase 2 clinical development. Operations center on advancing NK cell-based treatments for hematologic malignancies.

Who are the top competitors of Cyto-Sen Therapeutics?

Cyto-Sen Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.

Who are Cyto-Sen Therapeutics's investors?

Cyto-Sen Therapeutics has 1 investor. Key investors include Kiadis Pharma.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available